MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 2, 2005; DOI: 10.1124/mol.105.014944


0026-895X/05/6805-1203-1213$20.00
Mol Pharmacol 68:1203-1213, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.014944v1
68/5/1203    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z. Y.
Right arrow Articles by Tseng, C.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z. Y.
Right arrow Articles by Tseng, C.-C.

15-Deoxy-{Delta}12,14 Prostaglandin J2 Up-Regulates Krüppel-Like Factor 4 Expression Independently of Peroxisome Proliferator-Activated Receptor {gamma} by Activating the Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Signal Transduction Pathway in HT-29 Colon Cancer Cells

Zhi Yi Chen, and Chi-Chuan Tseng

Section of Gastroenterology, VA Boston Healthcare System and Boston University School of Medicine, Boston, Massachusetts

15-Deoxy-{Delta}12,14 prostaglandin J2 (15d-PGJ2) is a natural ligand for the peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) that exhibits antiproliferative activity in colon cancer cells, but its mechanism of action is still poorly understood. In this study, we showed that Krüppel-like factor 4 (KLF4) is one of the downstream effectors of 15d-PGJ2. Treatment of HT-29 cells with 15d-PGJ2 resulted in up-regulation of both KLF4 mRNA and protein expression, and these increases were also observed in other colon cancer cell lines. Down-regulation of KLF4 expression by small interfering RNA (siRNA) targeting KLF4 reduced 15d-PGJ2-mediated G1 phase arrest, suggesting that KLF4-mediated function of 15d-PGJ2. The effect of 15d-PGJ2 on KLF4 expression seems not to involve its nuclear receptor PPAR{gamma}, in that our data show that:1) KLF4 gene promoter does not contain putative PPRE sequence, 2) 15d-PGJ2 rapidly activates extracellular signal-regulated kinase (ERK) and induces KLF4 mRNA expression, 3) KLF4 is induced by 15d-PGJ2 but not by rosiglitazone, a synthetic PPAR{gamma} ligand, and 4) 15d-PGJ2 is unable to stimulate PPAR-dependent promoter activity in the absence of cotransfected PPAR{gamma}. Moreover, 15d-PGJ2-mediated KLF4 mRNA expression was blocked by 2'-amino-3'-methoxyflavone (PD98059) or 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126), two ERK kinase MAP inhibitors, whereas the phosphoinositol-3 kinase inhibitors wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) had no such effect. Furthermore, KLF4 induction by 15d-PGJ2 occurred only in signal transducer and activator of transcription 1 (STAT1)-expressing, not in STAT1-knockout cells. Together, these results suggest that 15d-PGJ2-induced growth inhibition of colon cancer cells is mediated, at least in part, through up-regulation of KLF4 expression. This induction is unlikely to be mediated through the PPAR{gamma} receptor but may involve the mitogen-activated protein kinase kinase/ERK pathway and is STAT1-dependent.


Received for publication May 19, 2005.

Accepted for publication August 2, 2005.

Address correspondence to: Dr. Zhi Yi Chen, Section of Gastroenterology, Boston University School of medicine EBRC X-513, 650 Albany Street, Boston, MA 02118. E-mail: zhiyi.chen{at}bmc.org




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. D. Cho, S. Chintharlapalli, M. Abdelrahim, S. Papineni, S. Liu, J. Guo, P. Lei, A. Abudayyeh, and S. Safe
5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells
Mol. Cancer Ther., July 1, 2008; 7(7): 2109 - 2120.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Chintharlapalli, S. Papineni, I. Jutooru, A. McAlees, and S. Safe
Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells
Mol. Cancer Ther., May 1, 2007; 6(5): 1588 - 1598.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Zeng, S. Zhuang, J. Gloddek, C.-C. Tseng, G. R. Boss, and R. B. Pilz
Regulation of cGMP-dependent Protein Kinase Expression by Rho and Kruppel-like Transcription Factor-4
J. Biol. Chem., June 23, 2006; 281(25): 16951 - 16961.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
O. Schroder, Y. Yudina, A. Sabirsh, N. Zahn, J. Z. Haeggstrom, and J. Stein
15-deoxy-{Delta}12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells
J. Lipid Res., May 1, 2006; 47(5): 1071 - 1080.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Toxicol. Sci., April 1, 2006; 90(2): 269 - 295.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics